CN Patent

CN121195310A — Hr阳性her2阴性乳腺癌的分型系统和方法

Assigned to Luming Medical Technology Huzhou Co ltd · Expires 2025-12-23 · 0y expired

What this patent protects

本发明涉及一种新的HR阳性HER2阴性乳腺癌分型系统和方法，根据HR阳性HER2阴性乳腺癌的多组学结果，将HR阳性HER2阴性乳腺癌分为经典腔面型、免疫调控型、增殖型和受体酪氨酸激酶驱动型这四种亚型。针对这四种亚型分别采用不同的治疗方案，能够实现不同亚型HR阳性HER2阴性乳腺癌的精准治疗。本发明还涉及基于AI数字病理或分类器基因表达的HR阳性HER2阴性乳腺癌分型方法。

USPTO Abstract

本发明涉及一种新的HR阳性HER2阴性乳腺癌分型系统和方法，根据HR阳性HER2阴性乳腺癌的多组学结果，将HR阳性HER2阴性乳腺癌分为经典腔面型、免疫调控型、增殖型和受体酪氨酸激酶驱动型这四种亚型。针对这四种亚型分别采用不同的治疗方案，能够实现不同亚型HR阳性HER2阴性乳腺癌的精准治疗。本发明还涉及基于AI数字病理或分类器基因表达的HR阳性HER2阴性乳腺癌分型方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN121195310A
Jurisdiction
CN
Classification
—
Expires
2025-12-23
Drug substance claim
No
Drug product claim
No
Assignee
Luming Medical Technology Huzhou Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.